For example, retreatment with the MEK inhibitor selumetinib has been shown to be effective for tumor control in melanoma and may suggest drug resistance to these agents is reversible, unlike other small molecule inhibitors used in cancer (53). The gene discussed is MAP2K7; the disease is neoplasm.